Currently, CDK4/6 inhibitors are the first-line treatment for HR+, HER2-, advanced breast cancer, with both abemaciclib and ribociclib receiving FDA approval for use in early breast cancer (Morrison et al., 2024). This evidence concerns the gene CDK4 and breast carcinoma.